Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding trial of norucholic acid in primary biliary cholangitis with inadequate response to ursodeoxycholic acid
2021-001431-56Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in primary biliary cholangitis (PBC) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Primary endpoint: mean relative change in alkaline phosphatase. Started Nov 2021; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2021-001431-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001431-56.